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OBJECTIVE — Debateremainsastowhethershort-orlong-termglycemicinstabilityconfers
a risk of microvascular complications in addition to that predicted by mean glycemia alone. In
thisstudy,weanalyzeddatafromtheDiabetesControlandComplicationsTrial(DCCT)toassess
the effect of A1C variability on the risk of retinopathy and nephropathy in patients with type 1
diabetes.
RESEARCH DESIGN AND METHODS — A1C was collected quarterly during the
DCCT in 1,441 individuals. The mean A1C and the SD of A1C variability after stabilization of
glycemia(from6monthsonwards)werecomparedwiththeriskofretinopathyandnephropathy
with adjustments for age, sex, disease duration, treatment group, and baseline A1C.
RESULTS — Multivariate Cox regression showed that the variability in A1C added to mean
A1C in predicting the risk of development or progression of both retinopathy (hazard ratio 2.26
for every 1% increase in A1C SD [95% CI 1.63–3.14], P  0.0001) and nephropathy (1.80
[1.37–2.42], P  0.0001), with the relationship a feature in conventionally treated patients in
particular.
CONCLUSIONS — This study has shown that variability in A1C adds to the mean value in
predictingmicrovascularcomplicationsintype1diabetes.Thus,incontrasttoanalysesofDCCT
data investigating the effect of short-term glucose instability on complication risk, longer-term
ﬂuctuations in glycemia seem to contribute to the development of retinopathy and nephropathy
in type 1 diabetes.
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T
he effect that glycemic variability
may have on the risk of develop-
ment of microvascular complica-
tions of diabetes remains controversial
(1). Studies such as the Diabetes Control
and Complications Trial (DCCT) in type
1 diabetes and the UK Prospective Diabe-
tesStudy(UKPDS)intype2diabeteshave
left little doubt that the risk of microvas-
cular complications rises exponentially as
mean blood glucose (assessed using A1C)
increases (2–5). However, with regard to
glycemic variability, the clinical evidence
has not been consistent. For example, in
the DCCT the rate of complications at a
given value of A1C was apparently higher
in the conventionally treated patients
than in those treated intensively (3), lead-
ing to the suggestion that this result may
be a consequence of larger glycemic ex-
cursionsintheformergroupofpatientsas
they received fewer injections of insulin
perday(6).Nonetheless,furtheranalyses
of the DCCT dataset has shown that
within-day glucose variability, using
seven-point laboratory measured glucose
proﬁles, had no additional inﬂuence on
the risk of micro- or macrovascular com-
plication risk beyond that predicted by
the mean glucose value alone (7–9). A
more recent reanalysis of the A1C data by
the DCCT group has shown that the orig-
inaldifferencesbetweentreatmentgroups
was probably an artifact of model as-
sumptions originally used and that no
discrepancies in microvascular risk at the
sameA1Cactuallyexisted(10).Indeed,it
has subsequently been suggested that the
increased complication risk in conven-
tionally treated patients was simply be-
cause their blood glucose values were
highercomparedwiththoseofintensively
treated patients at the same A1C (11).
It is also currently unknown whether
short-term (within-day) variability may
have a different inﬂuence on complications
compared with longer-term (day-to-day or
week-to-week) glucose ﬂuctuations. Cer-
tainly, data from the Pittsburgh Epidemiol-
ogy Study showed that A1C variability
seemedtobeanadditionalriskfactorforthe
development of macrovascular complica-
tions (12).
It is fundamental to managing diabe-
tes for a clinician to know whether a pa-
tient with glucose instability has a higher
risk of microvascular complications than
one without, especially because many of
the recent pharmacological advances
have focused on reducing glucose vari-
ability(aswellasmeanglucose)largelyby
targeting postprandial hyperglycemia.
Therefore, in this current study we have
analyzed the publicly available DCCT
dataset to investigate the potential for
A1C variability to have an inﬂuence on
microvascular complications.
RESEARCH DESIGN AND
METHODS— We used the publicly
accessible datasets collected by the
DCCT, which were stored in SAS format
(http://www.gcrc.umn.edu). The DCCT
was a 9-year follow-up study of 1,441
participants with type 1 diabetes compar-
ing the effect of intensive versus conven-
tional blood glucose management on the
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plications of diabetes. At randomization,
patients were stratiﬁed into one of two
cohorts. The primary prevention cohort
(n  726) had no evidence of retinopathy
by fundus photography and a urinary al-
buminexcretionrate(AER)40mg/24h
(28 g/min). The secondary prevention
cohort (n  715) had only minimal reti-
nopathy,andanAER200mg/24h(140
g/min). The study participants were
randomly assigned into intensive (n 
711) and conventional (n  730) treat-
ment groups.
Deﬁnition of events
Severity of retinopathy was determined
by the 25-point Early Diabetic Retinopa-
thy Treatment Study (EDRTS) interim
score (2). The development and progres-
sion of sustained retinopathy was deﬁned
as a change from baseline of 3 units on
the EDRTS score on any two successive
annual evaluations. During the 9 years of
follow-up, 242 individuals developed
sustained retinopathy, 67 of whom were
intheintensivetreatmentgroup.Nephro-
pathy was deﬁned as an increase in AER
40 mg/24 h (28 g/min) on any annual
evaluation providing that the baseline
AER was 40 mg/dl (28 g/min). The
mean age was 27 years (range 13–39
years). Just over half (n  761, 52.8%)
were men. Average BMI was 23.4 kg/m
2;
2% had a BMI 30 kg/m
2. Nearly all
participants were Caucasian. The median
disease duration was 4 years. Approxi-
mately one-ﬁfth declared themselves as
current smokers.
A1C measurement and statistical
methods
A1C was measured quarterly in both
treatment groups. In this analysis, we
only used data from 6 months into the
trial because the subjects in the inten-
sively treated group were undergoing a
period of rapidly changing glycemic con-
trol before reaching an A1C nadir at 6
months. The relationship between A1C
and the development of diabetes compli-
cations was assessed by Cox regression
from which hazard ratios (HRs) and 95%
CIs were calculated. The Cox regression
model is semiparametric in the sense that
noassumptionconcerningevent-freesur-
vival times is necessary; it is based on the
assumption that the effect of a risk factor,
expressedasanHR,isconstantovertime.
The assumption of proportionality of the
Cox model covariates was tested by plot-
ting Schoenfeld residuals. All Cox regres-
sion models were adjusted for the
following baseline covariates: age (years),
sex, disease duration (years), randomiza-
tion treatment (conventional versus in-
tensive), prevention cohort (primary
versus secondary), and A1C at the study
eligibility stage.
Three models were constructed. The
ﬁrst looked solely at the inﬂuence of the
updated mean A1C, from 6 months on-
wards, on the risk of subsequent micro-
vascular complications, whereas the
second model also included the variabil-
ity in A1C throughout the period ex-
pressed as SDs of A1C over all visits. As
the number of visits an individual patient
had could also inﬂuence this SD (such
that few visits would make the SD appar-
ently greater than many visits), the SD
valuewasalsodividedby[n/(n1)]to
adjustforthispossibility.Thethirdmodel
expressed A1C variability as an updated
time-dependent SD (3).
Patients in the conventionally treated
group who became pregnant were un-
blinded to their A1C values and treated
with a goal of near-normal glycemia, be-
fore returning to the conventional treat-
ment protocol after delivery (13). To
ensure that our results were not inﬂu-
enced by these 86 individuals, a separate
analysis that excluded these patients was
performed.
There has been considerable interest
in calculating coefﬁcients of determina-
tion (r
2) in models other than those for
least-squares regression. Many research-
ershavelookedatdevelopinganr
2equiv-
alent for the Cox proportional hazards
model.However,thedifﬁcultyliesinhow
to take censoring into account. Because
thereisnoconsensusonhowbesttomea-
sure r
2 for the Cox model (14), we have
not pursued it here.
The GLIM4 and SPSS statistical com-
puter packages were used to analyze the
data. An arbitrary level of 5% statistical
signiﬁcance (two-tailed) was assumed.
RESULTS— A1C variability was
greater in the conventionally treated pa-
tients than in those treated intensively
(A1C SD 0.86 vs. 0.59). Variability was
also closely related to the mean A1C of all
patients (r  0.55), being especially so in
intensively treated patients compared
with conventionally treated patients (r 
0.71 vs. r  0.32).
Table 1 shows the relationship be-
tween the updated mean A1C and both
retinopathy and nephropathy risk in the
intensively treated group, conventionally
treatedgroup,andbothgroupscombined
(model1).Models2and3showtheeffect
of including A1C variability (either as the
SD over the entire study duration or as an
updated SD) within the same model. In
eachcaseinwhichmeanA1Cwasinitially
predictive of complications, A1C SD ei-
ther added to (or explained) the risk indi-
cated by the mean value of A1C alone.
ExpressingSDafterdividingby[n/(n
1)] made no difference as to the effect of
A1C variability on complication risk. In
addition, limiting the analysis to only
thoseconventionallytreatedpatientswho
had not become pregnant during the
DCCT did not alter the ﬁndings. For ex-
ample, in model 2, the HR for SD among
nonpregnant conventionally treated pa-
tients was 2.2 (95% CI 1.4–3.4).
Figure 1A shows the relative risk of
retinopathy progression using both treat-
ment groups combined in model 2 (Table
1) when applied to DCCT patients in the
range of 0–97.5th centile of mean A1C
after adjustment for A1C SD, using the
2.5th centile as a reference. Figure 1B
shows the same patients over the same
range of A1C SD after adjustment for
mean A1C.
CONCLUSIONS — This analysis of
the DCCT data has shown that in patients
withtype1diabetes,increasingvariability
in A1C adds to the risk of microvascular
complications over and above that pre-
dicted by the mean A1C value alone. This
ﬁnding was present in the DCCT cohort
overall and was also a feature of both
treatment groups individually when the
mean A1C alone was initially predictive.
The effect was most pronounced among
those patients who were in the conven-
tionally treated group, presumably be-
cause the event rate, the range of
variability, and the spread of variability at
any given mean A1C was much larger
than those for patients in the intensively
treated patients.
The magnitude of the effect of A1C
variability is marked, such that a 1% ab-
solute increase in A1C SD results in at
least a doubling in retinopathy and an
80% increase in nephropathy risk using
eitherofourmodels.AsshowninFig.1B,
put into the context of individuals partic-
ipating in the DCCT, it means that a
patient in the 97.5th centile of A1C vari-
ability (SD 1.87%) has more than three
times the retinopathy risk and more than
twice the nephropathy risk of a patient in
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A1C. The ﬁndings are in contrast to those
of a previous analysis of the DCCT data,
which suggested that A1C variability had
little effect on complication risk (3), but
probably included all patient visits, in-
cluding those before A1C stabilized at 6
months in intensively treated patients.
There are several possible reasons
for the current ﬁndings. One is that me-
dium- to long-term ﬂuctuation in blood
glucose truly is an additional risk for the
development of microvascular complica-
tions. This ﬂuctuation is in contrast to
within-day glucose variability, which
showed little inﬂuence on retinopathy or
nephropathy risk in the same patients in
the DCCT (7,8). The latter ﬁnding was
surprising because numerous studies
have shown that short-term glycemic ex-
cursions lead to an overproduction of re-
active oxygen species in cell cultures (15)
as well as in patients with type 2 diabetes
(16) (though not conﬁrmed in type 1
[17]). There are also data on the effect of
longer-term changes in glycemia on free
radical production (18) as well as both
clinical and laboratory evidence that pe-
riods of sustained hyperglycemia are “re-
membered” and so place patients at
highersubsequentlong-termriskofcom-
plications (19,20). In this regard, the det-
rimental effect of A1C variability may be
mediated through the same mechanism
underlying that of the “metabolic mem-
ory” phenomenon (20,21).
An alternative possible explanation
for our data relates to the fact that the risk
of microvascular complications seems to
rise exponentially, rather than linearly, as
A1C rises (2,3). Thus, although patients
who have more variable A1C values will
be spending the same time above and be-
low their mean value as another with
comparatively stable A1C, their average
riskwillbehigherbecausetheirperiodsof
sustained glycemia far above their mean
will be placing them at an especially
highcomplicationrisk,whichwillmore
than cancel out any reduction in risk
resulting from them also having equal
periods far below their mean. If true, it
would be expected that this effect
would be exaggerated as the individu-
al’s mean A1C was higher, which may
be one reason why the inﬂuence of A1C
variability seems greater in convention-
ally treated patients.
Another possible reason linking A1C
ﬂuctuations with complication risk is the
consistent observation that improving
glycemic control can lead to a short-term
worsening in retinopathy (22,23) before
subsequently resulting in a net long-term
improvement (23): the “normoglycemic
reentryphenomenon.”Indeed,thepoten-
tial for early retinopathy worsening was
one of the main concerns of improving
glucose control when the DCCT was con-
ceived. The mechanism for this paradox-
icaldeteriorationisnotfullyknownbutis
thought to involve changes in ocular
blood ﬂow and increased IGF-1 concen-
trations (24) consequent on improved
glycemiccontrol.Whateverthecause,the
cyclical improvements in glycemic con-
trol found in patients with more variable
A1C could result in a cyclical worsening
ofretinopathy,whichisinadditiontothat
predicted by the mean A1C value alone.
This excess risk, of course, could also be
compounded by the intervening periods
of worsening control. In opposition to
this hypothesis is the fact that the early
worsening of nephropathy after glycemic
improvementisnotwellrecognized(with
the possible exception of patients in the
DCCT who became pregnant) (13), al-
though this may be more a reﬂection of
retinalchangesbecomingapparentbefore
those of urinary albumin.
These explanations may partially re-
concile why short-term (within-day) glu-
cose variability in the same patients has
been found to have little effect on micro-
vascular risk (7,8), whereas longer-term
instability in the form of A1C has been
found here to be much more predictive.
Alternatively, it is possible that A1C is
Table 1—Inﬂuence of updated mean A1C alone (model 1), inclusive of mean A1C SD (model 2), or updated mean A1C (model 3) on
complication risk
Intensive group HR
(95% CI) P value
Conventional group HR
(95% CI) P value
Combined HR
(95% CI) P value
Model 1
Retinopathy
Mean A1C 1.20 (1.04–1.39) 0.016 1.24 (1.12–1.36) 0.0001 1.22 (1.12–1.32) 0.0001
Nephropathy
Mean A1C 1.06 (0.96–1.17) 0.24 1.21 (1.10–1.33) 0.0001 1.13 (1.05–1.22) 0.001
Model 2
Retinopathy
Mean A1C 1.15 (0.95–1.40) 0.16 1.18 (1.07–1.29) 0.001 1.17 (1.08–1.28) 0.0001
A1C SD 2.53 (1.36–4.68) 0.003 2.11 (1.42–3.20) 0.0001 2.26 (1.63–3.14) 0.0001
Nephropathy
Mean A1C 1.052 (0.89–1.23) 0.54 1.15 (1.04–1.27) 0.005 1.11 (1.02–1.21) 0.009
A1C SD 1.51 (0.88–2.60) 0.14 2.30 (1.57–3.37) 0.0001 1.80 (1.37–2.42) 0.0001
Model 3
Retinopathy
Mean A1C 1.09 (0.97–1.23) 0.17 1.18 (1.07–1.31) 0.001 1.14 (1.05–1.24) 0.002
Updated A1C SD 3.22 (1.95–5.32) 0.0001 1.70 (1.14–2.52) 0.009 2.11 (1.54–2.89) 0.0001
Nephropathy
Mean A1C 1.03 (0.94–1.13) 0.52 1.15 (1.04–1.27) 0.004 1.08 (1.01–1.16) 0.027
Updated A1C SD 1.91 (1.21–3.10) 0.005 1.94 (1.34–2.89) 0.0001 1.86 (1.41–2.47) 0.0001
Models were adjusted for age, sex, duration, intervention group (when groups were combined), and A1C at eligibility: A1C time dependent and blood glucose time
dependent. Models used were from 6 months onward.
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glucose changes than daily glucose pro-
ﬁles, although the same DCCT data have
shown the mean glucose, rather than glu-
cose variability, has the major inﬂuence
on the A1C value (25).
There do not seem to be many lim-
itations in this study related to the size
and completeness of the dataset, which
isareﬂectionoftherigorousprotocolof
the DCCT and of the dedication of the
patients involved. In sum total, the
1,441individualshad31,260A1Cmea-
surements performed from 6 months
intothestudyonwhichtobaseourcon-
clusions. It must also not be forgotten
that the study beneﬁted by being per-
formed before other potential confound-
ing factors such as antihypertensive and
lipid-loweringagentscameintocommon
use. Nevertheless, in interpreting these
data, it should also be remembered that
A1CintheDCCTasawholeexplainedno
more than 23% of the risk of retinopathy
progressionfortheentirecohort,withthe
risk reduction associated with intensive
treatment rather than conventional treat-
ment A1C values being just a fraction of
this percentage (3).
In summary, this study has shown
that longer-term ﬂuctuations in glycemia
seemtoindependentlyrelatetothedevel-
opment of retinopathy and nephropathy
in type 1 diabetes. Thus, sole measure-
ment of mean glucose or mean A1C may
not be the best predictor of complication
risk.
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